

**Company: BiomX**

**Website:** <https://www.biomx.com/>

**CEO: Jonathan Solomon**

**CATEGORY: Biotech/Pharma**

- **(I&I) Immunology and Inflammation Reclaim top Priorities in BioPharma: Driver and Opportunities?**

- **Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.**

BiomX develops natural and engineered phage therapies to combat harmful bacteria, addressing the global challenge of antimicrobial resistance in chronic diseases. BiomX has advanced programs in Phase 2 clinical trials targeting chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. Key investors and partners include the Deerfield, CF Foundation, OrbiMed, AMR Action Fund, and the US Navy.

- **Core Technology What is the technology, its uniqueness, and its value proposition?**

The **BOLT platform** (“Bacteriophage Lead to Treatment”) integrates proprietary computational tools, automated screening, synthetic engineering, and validation assays to develop natural or engineered phage cocktails targeting specific pathogenic bacteria. Optimized for host range and resistance to address broad patient populations, the platform supports go-to-market broad bacteriophage cocktail development within 1–2 years.

- **Product Profile/Pipeline Briefly describe the company’s product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.**

BiomX develops bacteriophage cocktails for chronic infections, including cystic fibrosis (CF) and diabetic foot infections & osteomyelitis, with market potentials of \$1.5 billion and \$2.5 billion worldwide, respectively. Pipeline highlights: Preparing Phase 2/3 study pending FDA discussions following DFO positive phase 2 readout (WRAIR/US Navy), Phase 2 CF readout (CF Foundation) expected in Q1 2026.

- **Business Strategy Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.**

Execute phage therapy development through lead programs in diabetic foot infections and osteomyelitis (DFI/DFO) and cystic fibrosis (CF), targeting commercialization following Phase 3 trials, considering potential Phase 3 partnerships. Leverage BOLT

technology partnerships to launch additional bacteriophage cocktails for new indications, expanding therapeutic applications and market opportunities.

- **What's Next?**

BiomX is preparing for Phase 2/3 trial of BX211 in Diabetic foot infection and osteomyelitis, pending regulatory discussions, and BX004 Phase 2 readout for cystic fibrosis (CF) readout is expected first quarter of 2026. Additionally, BiomX plans to explore options to launch a Phase 2 study of BX004 in non-cystic fibrosis bronchiectasis (NCFB), a larger indication de-risked by prior BX004 studies in CF.